Immunocore Reports Second Quarter Financial Results And Provides A Business Update

RefinitivMeno di 1 minuto di lettura

Immunocore Holdings PLC IMCR:

IMMUNOCORE REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
IMMUNOCORE : PHASE 3 TEBE-AM TRIAL REMAINS ON SCHEDULE TO COMPLETE ENROLLMENT IN THE FIRST HALF OF 2026
IMMUNOCORE : KIMMTRAK®(TEBENTAFUSP-TEBN) NET REVENUES OF $98.0 MILLION IN Q2 2025

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Accedi o crea un account gratuito per leggere queste notizie